PolyPid Ltd:製品パイプライン分析

◆英語タイトル:PolyPid Ltd - Product Pipeline Analysis, 2017 Update
◆商品コード:DATA8010086
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月27日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥222,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥333,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PolyPid Ltd (PolyPid) is a clinical stage pharmaceutical company that develops, manufactures and commercialize drugs for extended release and local delivery. The company develops its products using PLEX (Polymer-Lipid Encapsulation MatriX) platform, which helps in products. PolyPid’s pipeline product candidates include BonyPid-1000 and BonyPid-500, both of which are bone graft materials for filling bone voids and defects, and D-Plex, an antibiotic drug reservoir, which can be implanted during surgical procedures for prolonged infection management over several weeks and minimizes the potential side effects and lowers the cost of treatment significantly, localized medication solution is essential in many treatment regimens. The company has partnerships with various organizations such as MIS Dental Implants Ltd, Rimonim and BALI to develop novel products. PolyPid is headquartered in Petach Tikva, Israel.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company PolyPid Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
PolyPid Ltd Company Overview 4
PolyPid Ltd Company Snapshot 4
PolyPid Ltd Pipeline Products and Ongoing Clinical Trials Overview 4
PolyPid Ltd – Pipeline Analysis Overview 7
PolyPid Ltd – Key Facts 7
PolyPid Ltd – Major Products and Services 8
PolyPid Ltd Pipeline Products by Development Stage 9
PolyPid Ltd Ongoing Clinical Trials by Trial Status 11
PolyPid Ltd Pipeline Products Overview 13
BonyPid-1000 13
BonyPid-1000 Product Overview 13
BonyPid-1000 Clinical Trial 14
BonyPid-500 15
BonyPid-500 Product Overview 15
BonyPid-500 Clinical Trial 16
D-PLEX 17
D-PLEX Product Overview 17
D-PLEX Clinical Trial 18
PolyPid Ltd – Key Competitors 19
PolyPid Ltd – Key Employees 20
PolyPid Ltd – Key Employee Biographies 21
PolyPid Ltd – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
PolyPid Ltd, Recent Developments 23
Dec 21, 2017: PolyPid Appoints Jacob Harel as Chairman of the Board of Directors 23
Aug 16, 2017: PolyPid Completes Enrollment in Phase Ib/II Study of D-PLEX in Post-Cardiac Surgery Sternal Infection 23
Mar 09, 2017: PolyPid Announces Positive Interim Data from Company’s Confirmatory Clinical Trial for BonyPid-1000 Antibiotic Eluting Bone Substitute 24
Mar 08, 2017: PolyPid Announces Receipt of Qualified Infectious Disease Product Designation from FDA for D-PLEX in Post-Cardiac Surgery Sternal Infection 25
Dec 02, 2015: PolyPid Announces First Patient Enrolled in Confirmatory Clinical Trial, Evaluating Performance and Safety of BonyPid-1000, an Antibiotic Eluting Bone Void Filler 25
Nov 19, 2015: PolyPid Announces Issuance of New U.S. Patent for Doxycycline Sustained Release Compositions 26
Jul 07, 2014: PolyPid Announces US Patent Allowance for Sustained Release of Nucleic Acid Matrix Compositions 26
Jun 18, 2014: PolyPid Wins First Prize at Biomed Startup Competition 27
Dec 10, 2012: PolyPid Announces Positive Preliminary Results Of Clinical Trial With BonyPid 27
Apr 23, 2012: PolyPid Joins Rimonim Consortium to Develop Delivery System for RNA-based Drugs 27
Appendix 29
Methodology 29
About GlobalData 31
Contact Us 31
Disclaimer 32

List of Tables
PolyPid Ltd Pipeline Products and Ongoing Clinical Trials Overview 4
PolyPid Ltd Pipeline Products by Equipment Type 5
PolyPid Ltd Pipeline Products by Indication 6
PolyPid Ltd Ongoing Clinical Trials by Trial Status 6
PolyPid Ltd, Key Facts 7
PolyPid Ltd, Major Products and Services 8
PolyPid Ltd Number of Pipeline Products by Development Stage 9
PolyPid Ltd Pipeline Products Summary by Development Stage 10
PolyPid Ltd Ongoing Clinical Trials by Trial Status 11
PolyPid Ltd Ongoing Clinical Trials Summary 12
BonyPid-1000 - Product Status 13
BonyPid-1000 - Product Description 13
BonyPid-1000 - Safety and Performance of BonyPid-1000 in the Treatment of Gustilo IIIA and IIIB Tibial Open Fractures 14
BonyPid-500 - Product Status 15
BonyPid-500 - Product Description 15
BonyPid-500 - PolyPid, Ltd. Pilot Study of the BonyPid-500 Bone Graft Substitute 16
D-PLEX - Product Status 17
D-PLEX - Product Description 17
D-PLEX - A Phase Ib/II Prospective, Multicenter, Two Part Study; Part 1 - Open Label, Single Arm and Part 2 Randomized, Single-blinded (Study to Assess Safety and Efficacy of D-PLEX Concomitantly with Standard of Care Versus Standard of Care Alone in the Prevention of Primary Sternal Infection Post Cardiac Surgery 18
PolyPid Ltd, Key Employees 20
PolyPid Ltd, Key Employee Biographies 21
Glossary 30

★海外企業調査レポート[PolyPid Ltd:製品パイプライン分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Surgical Information Systems LLC-医療機器分野:企業M&A・提携分析
    Summary Surgical Information Systems LLC (SIS) is a healthcare information technology company that develops and provides software solutions. The company offers anesthesia information management system, business and clinical analytics software, patient tracking system, tissue tracking and management …
  • Ramsay Health Care Ltd (RHC):企業の財務・戦略的SWOT分析
    Ramsay Health Care Ltd (RHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Meritor, Inc.:企業の戦略・SWOT・財務分析
    Meritor, Inc. - Strategy, SWOT and Corporate Finance Report Summary Meritor, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • AMETEK Inc (AME):医療機器:M&Aディール及び事業提携情報
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturing company that manufactures electronic instruments and electromechanical devices. The company's products include medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titanium alloys …
  • Universal Corporation:企業の戦略・SWOT・財務分析
    Universal Corporation - Strategy, SWOT and Corporate Finance Report Summary Universal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Circassia Pharmaceuticals Plc (CIR):製薬・医療:M&Aディール及び事業提携情報
    Summary Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease …
  • Nephros Inc (NEPH)-医療機器分野:企業M&A・提携分析
    Summary Nephros Inc (Nephros) is medical device company that develops and markets filtration products. The company offers infection control filters, dialysis ultrafilters, and hemodia filtration systems. Its dialysis ultrafilters are intended to be used to filter water and bicarbonate concentrate us …
  • True Corporation Public Company Limited:戦略・SWOT・企業財務分析
    True Corporation Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary True Corporation Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • MILEI GmbH:企業の戦略・SWOT・財務情報
    MILEI GmbH - Strategy, SWOT and Corporate Finance Report Summary MILEI GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Abivax SA (ABVX):企業の財務・戦略的SWOT分析
    Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce f …
  • Stryker Corporation (SYK)-医療機器分野:企業M&A・提携分析
    Summary Stryker Corporation (Stryker) is one of the leading manufacturers of medical equipment. It offers reconstructive, medical and surgical, and neurotechnology and spine products. Its major products include implants; surgical equipment and surgical navigation systems; endoscopic and communicatio …
  • The Home Depot, Inc.:企業の戦略・SWOT・財務情報
    The Home Depot, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Home Depot, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • The Advisory Board Company:企業の戦略的SWOT分析
    The Advisory Board Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Orexigen Therapeutics Inc (OREX)-製薬・医療分野:企業M&A・提携分析
    Summary Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased …
  • HollyFrontier Corporation:企業の戦略・SWOT・財務分析
    HollyFrontier Corporation - Strategy, SWOT and Corporate Finance Report Summary HollyFrontier Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • American Water Works Company, Inc.:企業の戦略・SWOT・財務情報
    American Water Works Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Water Works Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Dr. Reddy’s Laboratories Ltd (DRREDDY):企業の財務・戦略的SWOT分析
    Dr. Reddy's Laboratories Ltd (DRREDDY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Empresaria Group plc (EMR):企業の財務・戦略的SWOT分析
    Empresaria Group plc (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • BiondVax Pharmaceuticals Ltd (BVXV):企業の財務・戦略的SWOT分析
    Summary BiondVax Pharmaceuticals Ltd (BiondVax Pharmaceuticals) is a biopharmaceutical company that develops universal flu vaccine. The company provides lead product M-001 is a synthetic peptide-based protein that offers protection against human influenza virus strains including seasonal influenza s …
  • Daegu Bank Ltd:企業の戦略・SWOT・財務分析
    Daegu Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Daegu Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆